Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef

被引:28
作者
Allard, Sabine D. [1 ,2 ]
Pletinckx, Katrien [1 ]
Breckpot, Karine [1 ]
Heirman, Carlo [1 ]
Bonehill, Aude [1 ]
Michiels, Annelies [1 ]
van Baalen, Carel A. [3 ]
Gruters, Rob A. [3 ]
Osterhaus, Albert D. M. E. [3 ]
Lacor, Patrick [2 ]
Thielemans, Kris [1 ]
Aerts, Joeri L. [1 ]
机构
[1] Vrije Univ Brussels, Sch Med, Dept Phys & Immunol, Lab Mol & Cellular Therapy, B-1090 Brussels, Belgium
[2] Univ Ziekenhuis St Rafael, Dept Int Med & Infect Dis, AIDS Unit, B-1090 Brussels, Belgium
[3] Erasmus MC, Dept Virol, NL-3015 GD Rotterdam, Netherlands
关键词
early expressed HIV-1 proteins; therapeutic vaccine; dendritic cells;
D O I
10.1016/j.vaccine.2008.04.077
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The limitations of highly active anti-retroviral therapy (HAART) have necessitated the development of alternative therapeutic strategies. One of the approaches that has gained prominence in recent years is therapeutic vaccination. We decided to assess the capacity of mature dendritic cells, derived from blood monocytes of HIV-1 infected patients, to generate functional T-cell responses. For this purpose, we constructed a chimeric mRNA encoding the proteins Tat, Rev and Nef. The TaReNef encoding information was linked to the HLA class II-targeting sequence of DC-LAMP. Broadly directed HIV-specific CD4(+) and CD8(+) cytotoxic T cells exhibiting a poly-functional cytokine secretion pattern were generated by co-culturing with autologous chimeric mRNA electroporated dendritic cells. Thus, administration of ex vivo generated dendritic cells expressing the early proteins Tat, Rev and Nef might offer a promising approach for therapeutic vaccination in HIV-1 infection. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3735 / 3741
页数:7
相关论文
共 46 条
[31]   Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation [J].
Peng, B ;
Robert-Guroff, M .
IMMUNOLOGY LETTERS, 2001, 78 (03) :195-200
[32]   HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [J].
Pitcher, CJ ;
Quittner, C ;
Peterson, DM ;
Connors, M ;
Koup, RA ;
Maino, VC ;
Picker, LJ .
NATURE MEDICINE, 1999, 5 (05) :518-525
[33]   mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation [J].
Ponsaerts, P ;
Van Tendeloo, VFI ;
Cools, N ;
Van Driessche, A ;
Lardon, F ;
Nijs, G ;
Lenjou, M ;
Mertens, G ;
Van Broeckhoven, C ;
Van Bockstatele, DR ;
Berneman, ZN .
LEUKEMIA, 2002, 16 (07) :1324-1330
[34]   EXPRESSION KINETICS AND SUBCELLULAR-LOCALIZATION OF HIV-1 REGULATORY PROTEINS NEF, TAT AND REV IN ACUTELY AND CHRONICALLY INFECTED LYMPHOID-CELL LINES [J].
RANKI, A ;
LAGERSTEDT, A ;
OVOD, V ;
AAVIK, E ;
KROHN, KJE .
ARCHIVES OF VIROLOGY, 1994, 139 (3-4) :365-378
[35]   MISSENSE MUTATIONS IN AN INFECTIOUS HUMAN IMMUNODEFICIENCY VIRAL GENOME - FUNCTIONAL MAPPING OF TAT AND IDENTIFICATION OF THE REV SPLICE ACCEPTOR [J].
SADAIE, MR ;
RAPPAPORT, J ;
BENTER, T ;
JOSEPHS, SF ;
WILLIS, R ;
WONGSTAAL, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (23) :9224-9228
[36]   Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection [J].
Shanker, P ;
Russo, M ;
Harnisch, B ;
Patterson, M ;
Skolnik, P ;
Lieberman, J .
BLOOD, 2000, 96 (09) :3094-3101
[37]   Comparison of the efficacy of early versus late viral proteins in vaccination against SIV [J].
Stittelaar, KJ ;
Gruters, RA ;
Schutten, M ;
van Baalen, CA ;
van Amerongen, G ;
Cranage, M ;
Liljeström, P ;
Sutter, G ;
Osterhaus, ADME .
VACCINE, 2002, 20 (23-24) :2921-2927
[38]   Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells [J].
Tuyaerts, S ;
Michiels, A ;
Corthals, J ;
Bonehill, A ;
Heirman, C ;
De Greef, C ;
Noppe, SM ;
Thielemans, K .
CANCER GENE THERAPY, 2003, 10 (09) :696-706
[39]   Generation of large numbers of dendritic cells in a closed system using Cell Factories™ [J].
Tuyaerts, S ;
Noppe, SM ;
Corthals, J ;
Breckpot, K ;
Heirman, C ;
De Greef, C ;
Van Riet, I ;
Thielemans, K .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 264 (1-2) :135-151
[40]  
van Baalen CA, 2002, EUR J IMMUNOL, V32, P2644, DOI 10.1002/1521-4141(200209)32:9<2644::AID-IMMU2644>3.0.CO